Breaking Down Beijing SL Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Investors tracking Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) should note a mixed financial picture: quarterly revenue of CNY 153.89 million for the period ending September 30, 2025 (a 3.63% sequential rise) sits against a troubling TTM revenue of CNY 578.61 million (down 26.04% YoY) and 2024 annual revenue of CNY 660.42 million (a 35.15% decline), while profit metrics show a nine‑month net income turnaround to CNY 141.1 million from a prior loss of CNY 16.74 million and EPS of CNY 0.1373, yet operating margins remain negative at -11.27% with four consecutive quarters of operating losses; balance sheet strengths include a net cash position of CNY 1.11 billion, equity of CNY 5.63 billion (book value per share CNY 5.47), working capital of CNY 2.23 billion and net cash per share of CNY 1.08, while market valuation shows a market cap of CNY 8.15 billion (up 7.16% over the past year), P/E of 95.05, P/B of 1.35 and P/S of 14.08-factors that, together with risks like revenue concentration, industry competition and regulatory exposure and opportunities such as international partnerships, rising production (projected >5 million units in 2023 vs 4.5 million in 2022) and R&D investment (CNY 500 million in 2022) make a deep dive into the full analysis essential for any informed investment decision-read on for the detailed breakdown.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Revenue Analysis

• Quarter ending September 30, 2025: revenue CNY 153.89 million, up 3.63% versus the prior quarter.
• Trailing twelve months (TTM) revenue: CNY 578.61 million, down 26.04% year-over-year.
• Full year 2024 revenue: CNY 660.42 million, a decline of 35.15% from 2023.
• Revenue per employee: approximately CNY 650,850 (889 employees).
• Market capitalization (Dec 3, 2025): CNY 8.15 billion; P/S ratio: 14.08.
• Primary drivers of recent revenue decline: intensified competition and market saturation within the pharmaceutical sector.

• Implications of current metrics:
  • High P/S (14.08) relative to declining revenues suggests market pricing includes expectations of recovery or premium for product pipeline/strategic assets.
  • Revenue per employee near CNY 650k indicates moderate revenue productivity; continued revenue compression may pressure margins and per-employee economics.
  • Sequential quarterly growth (+3.63%) offers an early sign of stabilization, but TTM and FY declines highlight persistent demand or competitive challenges.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Profitability Metrics

Beijing SL Pharmaceutical Co., Ltd. posted a meaningful earnings turnaround in the nine months ended September 30, 2025, moving from a prior-year loss to positive net income, but operating results remain mixed with recurring operating losses.

• Net income (9M 2025): CNY 141.1 million (vs. net loss CNY 16.74 million in 9M 2024).
• Basic EPS from continuing operations (9M 2025): CNY 0.1373 (vs. loss per share CNY 0.0163 in 9M 2024).
• Return on equity (ROE): 1.5%.
• Net profit margin: 14.5%.
• Operating margin: -11.27%.
• Operating profits negative for the last four consecutive quarters.

A balanced view of profitability for Beijing SL Pharmaceutical requires reconciling the strong net margin and EPS recovery with continued negative operating margins and four straight quarters of negative operating profits - indicating non-operating items or one-off gains helped net income. Further context on revenue composition, cost structure, and non-operating items can be found here: Beijing SL Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Debt vs. Equity Structure

Beijing SL Pharmaceutical presents a conservative capital structure characterized by zero reported debt and a meaningful equity base. Key balance-sheet figures point to strong liquidity and a cushion for downside risk, while also implying limited financial leverage for rapid expansion.

• Cash and cash equivalents: CNY 1.11 billion
• No reported interest-bearing debt - net cash position: CNY 1.11 billion
• Equity (book value): CNY 5.63 billion
• Book value per share: CNY 5.47
• Net cash per share: CNY 1.08
• Working capital: CNY 2.23 billion

Implications for investors:

• Balance-sheet strength: The net cash position and CNY 2.23 billion working capital indicate high short-term resilience and low bankruptcy risk.
• Conservative financing: Zero debt reduces interest burden and financial risk, supporting stability during industry or macro volatility.
• Limited leverage for growth: The absence of debt and heavy cash holdings can constrain ability to pursue large acquisitions or rapid capital-intensive expansion without diluting equity or changing financing policy.
• Per-share safety buffer: Net cash per share of CNY 1.08 and book value per share of CNY 5.47 provide quantifiable downside protection for equity holders.

Further context on corporate background and business model is available here: Beijing SL Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Liquidity and Solvency

• Net cash position: CNY 1.11 billion - provides immediate coverage for short-term obligations and operational needs.
• Reported absence of debt - implies minimal financial leverage and low fixed financing costs.
• Positive net income in the most recent quarter - supports retained earnings and further strengthens solvency.
• Working capital and total liabilities are needed to calculate precise current and quick ratios; those detailed line items are not fully disclosed here, limiting ratio-based analysis.

• Inference pathway: If working capital (current assets - current liabilities) and total/current liabilities are provided, the current ratio = current assets ÷ current liabilities can be reconstructed; quick ratio requires inventory value to be subtracted from current assets.
• Practical implication: With CNY 1.11bn net cash and no debt, liquidity stress is unlikely under normal operating conditions, but absence of detailed current/quick ratios prevents a full short-term stress-test.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Valuation Analysis

• Price-to-Earnings (P/E): 95.05 - investors are paying a material premium for current earnings.
• Price-to-Book (P/B): 1.35 - modest premium to book value, suggesting some tangible asset support beneath the high earnings multiple.
• Price-to-Sales (P/S): 14.08 - the market is valuing each yuan of revenue at a high multiple, consistent with growth expectations or margin expansion hopes.
• Enterprise Value (EV): CNY 7.20 billion - lower than market capitalization, implying net cash (market cap CNY 8.15 billion as of Dec 3, 2025).
• Market Capitalization: CNY 8.15 billion (up 7.16% over the past year as of Dec 3, 2025).
• Interpretation: The elevated P/E suggests optimism about future growth despite recent revenue declines; investors appear willing to pay for anticipated recovery or pipeline value.

• Risk/Reward trade-off: High multiples amplify downside if growth disappoints; conversely, successful pipeline or margin improvements could validate the premium.
• Balance-sheet context: Net cash implied by EV-to-market-cap gap reduces short-term insolvency risk and provides optionality for investment, buybacks or M&A.
• Relative signals: P/E >> P/B suggests market is valuing intangibles (pipeline, IP, R&D potential) more than current tangible assets.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Risk Factors

• Operational losses: The company has reported negative operating profits in the last four consecutive quarters, indicating ongoing operational challenges.

Detailed quarterly operating profit (¥, millions):

• Revenue contraction: Revenue has declined over the past few years, consistent with increased competition and market saturation in the pharmaceutical sector.

Selected revenue trend (¥, millions):

• Balance sheet rigidity: The absence of debt limits leverage options for growth and reduces access to debt financing for expansion or M&A.

Key balance sheet snapshot (¥, millions):

• Valuation risk: The company trades at a high P/E ratio that suggests potential overvaluation if earnings fail to recover.

Valuation snapshot:

• Revenue concentration: Licensing income is heavily dependent on a small set of customers, increasing concentration risk if any key partner reduces collaboration.

Revenue concentration estimate:

• Regulatory and industry risk: As a pharmaceutical maker, operations and profitability are sensitive to regulatory changes, reimbursement policy shifts, and clinical/approval outcomes.

For company background and business model context, see: Beijing SL Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Growth Opportunities

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) is positioned to capitalize on both geographic expansion and product-line depth through strategic partnerships, capacity growth and sustained R&D investment. Key quantifiable drivers below outline near-term and medium-term opportunities for investors.

• Strategic distribution expansion: entered partnerships with leading firms in Europe and North America to enhance distribution networks and accelerate market entry for prescription and OTC products.
• Global-standard manufacturing: operates multiple facilities compliant with international standards (GMP/ICH-aligned processes) to support export volumes and quality-sensitive markets.
• Production scale-up: total production volume projected to exceed 5,000,000 units in 2023, up from 4,500,000 units in 2022 - a year-over-year increase of ~11.1% reflecting improved operational efficiency and an expanded product mix.
• Sustainability & CSR: commitment to affordable medication and public health outcomes, supported by ~¥200 million invested in community health initiatives and education in the past year, strengthening brand reputation and patient loyalty.
• R&D-driven pipeline growth: R&D expenditure of ¥500 million in 2022 to advance new drug candidates and support entry into higher-margin therapeutic segments.

• Commercial leverage: rising production capacity combined with international partners reduces per-unit fixed costs and shortens time-to-market for new formulations.
• Pipeline economics: sustained ¥500M R&D funding supports higher-value specialty drugs and lifecycle extensions that can lift gross margins over time.
• Reputation & demand elasticity: ¥200M in community spending enhances pricing resilience and uptake in domestic and select international markets.

For more on shareholder composition and investor behavior, see Exploring Beijing SL Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?